2023-10-012024-09-302024-09-30false09224293MEDICUSLEX LIMITED2025-06-04falseiso4217:GBPxbrli:pure092242932023-10-01092242932024-09-30092242932023-10-012024-09-30092242932022-10-01092242932023-09-30092242932022-10-012023-09-3009224293bus:SmallEntities2023-10-012024-09-3009224293bus:AuditExempt-NoAccountantsReport2023-10-012024-09-3009224293bus:FullAccounts2023-10-012024-09-3009224293bus:PrivateLimitedCompanyLtd2023-10-012024-09-3009224293core:WithinOneYear2024-09-3009224293core:AfterOneYear2024-09-3009224293core:WithinOneYear2023-09-3009224293core:AfterOneYear2023-09-3009224293core:ShareCapital2024-09-3009224293core:SharePremium2024-09-3009224293core:RevaluationReserve2024-09-3009224293core:OtherReservesSubtotal2024-09-3009224293core:RetainedEarningsAccumulatedLosses2024-09-3009224293core:ShareCapital2023-09-3009224293core:SharePremium2023-09-3009224293core:RevaluationReserve2023-09-3009224293core:OtherReservesSubtotal2023-09-3009224293core:RetainedEarningsAccumulatedLosses2023-09-3009224293core:LandBuildings2024-09-3009224293core:PlantMachinery2024-09-3009224293core:Vehicles2024-09-3009224293core:FurnitureFittings2024-09-3009224293core:OfficeEquipment2024-09-3009224293core:NetGoodwill2024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-09-3009224293core:ListedExchangeTraded2024-09-3009224293core:UnlistedNon-exchangeTraded2024-09-3009224293core:LandBuildings2023-09-3009224293core:PlantMachinery2023-09-3009224293core:Vehicles2023-09-3009224293core:FurnitureFittings2023-09-3009224293core:OfficeEquipment2023-09-3009224293core:NetGoodwill2023-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-09-3009224293core:ListedExchangeTraded2023-09-3009224293core:UnlistedNon-exchangeTraded2023-09-3009224293core:LandBuildings2023-10-012024-09-3009224293core:PlantMachinery2023-10-012024-09-3009224293core:Vehicles2023-10-012024-09-3009224293core:FurnitureFittings2023-10-012024-09-3009224293core:OfficeEquipment2023-10-012024-09-3009224293core:NetGoodwill2023-10-012024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3009224293core:ListedExchangeTraded2023-10-012024-09-3009224293core:UnlistedNon-exchangeTraded2023-10-012024-09-3009224293core:MoreThanFiveYears2023-10-012024-09-3009224293core:Non-currentFinancialInstruments2024-09-3009224293core:Non-currentFinancialInstruments2023-09-3009224293dpl:CostSales2023-10-012024-09-3009224293dpl:DistributionCosts2023-10-012024-09-3009224293core:LandBuildings2023-10-012024-09-3009224293core:PlantMachinery2023-10-012024-09-3009224293core:Vehicles2023-10-012024-09-3009224293core:FurnitureFittings2023-10-012024-09-3009224293core:OfficeEquipment2023-10-012024-09-3009224293dpl:AdministrativeExpenses2023-10-012024-09-3009224293core:NetGoodwill2023-10-012024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-10-012024-09-3009224293dpl:GroupUndertakings2023-10-012024-09-3009224293dpl:ParticipatingInterests2023-10-012024-09-3009224293dpl:GroupUndertakingscore:ListedExchangeTraded2023-10-012024-09-3009224293core:ListedExchangeTraded2023-10-012024-09-3009224293dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2023-10-012024-09-3009224293core:UnlistedNon-exchangeTraded2023-10-012024-09-3009224293dpl:CostSales2022-10-012023-09-3009224293dpl:DistributionCosts2022-10-012023-09-3009224293core:LandBuildings2022-10-012023-09-3009224293core:PlantMachinery2022-10-012023-09-3009224293core:Vehicles2022-10-012023-09-3009224293core:FurnitureFittings2022-10-012023-09-3009224293core:OfficeEquipment2022-10-012023-09-3009224293dpl:AdministrativeExpenses2022-10-012023-09-3009224293core:NetGoodwill2022-10-012023-09-3009224293core:IntangibleAssetsOtherThanGoodwill2022-10-012023-09-3009224293dpl:GroupUndertakings2022-10-012023-09-3009224293dpl:ParticipatingInterests2022-10-012023-09-3009224293dpl:GroupUndertakingscore:ListedExchangeTraded2022-10-012023-09-3009224293core:ListedExchangeTraded2022-10-012023-09-3009224293dpl:GroupUndertakingscore:UnlistedNon-exchangeTraded2022-10-012023-09-3009224293core:UnlistedNon-exchangeTraded2022-10-012023-09-3009224293core:NetGoodwill2024-09-3009224293core:IntangibleAssetsOtherThanGoodwill2024-09-3009224293core:LandBuildings2024-09-3009224293core:PlantMachinery2024-09-3009224293core:Vehicles2024-09-3009224293core:FurnitureFittings2024-09-3009224293core:OfficeEquipment2024-09-3009224293core:AfterOneYear2024-09-3009224293core:WithinOneYear2024-09-3009224293core:ListedExchangeTraded2024-09-3009224293core:UnlistedNon-exchangeTraded2024-09-3009224293core:ShareCapital2024-09-3009224293core:SharePremium2024-09-3009224293core:RevaluationReserve2024-09-3009224293core:OtherReservesSubtotal2024-09-3009224293core:RetainedEarningsAccumulatedLosses2024-09-3009224293core:NetGoodwill2023-09-3009224293core:IntangibleAssetsOtherThanGoodwill2023-09-3009224293core:LandBuildings2023-09-3009224293core:PlantMachinery2023-09-3009224293core:Vehicles2023-09-3009224293core:FurnitureFittings2023-09-3009224293core:OfficeEquipment2023-09-3009224293core:AfterOneYear2023-09-3009224293core:WithinOneYear2023-09-3009224293core:ListedExchangeTraded2023-09-3009224293core:UnlistedNon-exchangeTraded2023-09-3009224293core:ShareCapital2023-09-3009224293core:SharePremium2023-09-3009224293core:RevaluationReserve2023-09-3009224293core:OtherReservesSubtotal2023-09-3009224293core:RetainedEarningsAccumulatedLosses2023-09-3009224293core:NetGoodwill2022-10-0109224293core:IntangibleAssetsOtherThanGoodwill2022-10-0109224293core:LandBuildings2022-10-0109224293core:PlantMachinery2022-10-0109224293core:Vehicles2022-10-0109224293core:FurnitureFittings2022-10-0109224293core:OfficeEquipment2022-10-0109224293core:AfterOneYear2022-10-0109224293core:WithinOneYear2022-10-0109224293core:ListedExchangeTraded2022-10-0109224293core:UnlistedNon-exchangeTraded2022-10-0109224293core:ShareCapital2022-10-0109224293core:SharePremium2022-10-0109224293core:RevaluationReserve2022-10-0109224293core:OtherReservesSubtotal2022-10-0109224293core:RetainedEarningsAccumulatedLosses2022-10-0109224293core:AfterOneYear2023-10-012024-09-3009224293core:WithinOneYear2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-10-012024-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2024-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2024-09-3009224293core:Non-currentFinancialInstrumentscore:CostValuation2023-09-3009224293core:Non-currentFinancialInstrumentscore:AdditionsToInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:RevaluationsIncreaseDecreaseInInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:ProvidedReleasedInPeriodProvisionsForImpairmentInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:ImpairmentLossReversalProvisionsForImpairmentInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:AcquisitionsIncreaseInProvisionsForImpairmentInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:DisposalsDecreaseInProvisionsForImpairmentInvestments2023-09-3009224293core:Non-currentFinancialInstrumentscore:OtherIncreaseDecreaseInProvisionsForImpairmentInvestments2023-09-3009224293bus:Director12023-10-012024-09-3009224293bus:Director22023-10-012024-09-3009224293core:FurnitureFittingsToolsEquipment2023-09-3009224293core:FurnitureFittingsToolsEquipment2023-10-012024-09-3009224293core:FurnitureFittingsToolsEquipment2024-09-30

MEDICUSLEX LIMITED

Registered Number
09224293
(England and Wales)

Unaudited Financial Statements for the Year ended
30 September 2024

MEDICUSLEX LIMITED
Company Information
for the year from 1 October 2023 to 30 September 2024

Directors

DANBURY, Catriona Luise
DANBURY, Christopher Michael, Dr

Registered Address

1st Floor, Buckley House 31a The Hundred
Romsey
SO51 8GD

Registered Number

09224293 (England and Wales)
MEDICUSLEX LIMITED
Balance Sheet as at
30 September 2024

Notes

2024

2023

£

£

£

£

Fixed assets
Tangible assets336,956145,588
36,956145,588
Current assets
Debtors487,41493,542
Cash at bank and on hand62,82637,191
150,240130,733
Creditors amounts falling due within one year5(104,118)(74,184)
Net current assets (liabilities)46,12256,549
Total assets less current liabilities83,078202,137
Creditors amounts falling due after one year6(19,912)(29,925)
Net assets63,166172,212
Capital and reserves
Called up share capital150150
Profit and loss account63,016172,062
Shareholders' funds63,166172,212
The financial statements were approved and authorised for issue by the Board of Directors on 4 June 2025, and are signed on its behalf by:
DANBURY, Christopher Michael, Dr
Director
Registered Company No. 09224293
MEDICUSLEX LIMITED
Notes to the Financial Statements
for the year ended 30 September 2024

1.Accounting policies
Statutory information
The company is a private company limited by shares and registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.
Statement of compliance
The financial statements have been prepared in accordance with the Companies Act 2006 and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland including Section 1A Small Entities.
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, the financial reporting standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover policy
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services.
Employee benefits
Short-term employee benefits are measured at the undiscounted amount expected to be paid in exchange for the employee's services to the company. Where employees have accrued short-term benefits which the entity has not paid by the balance sheet date, an accrual is recognised within creditors: amounts falling due within one year together with an associated expense in profit or loss. The liabilities are classified as current obligations in the statement of financial position because they are expected to be settled wholly within twelve months after the end of the period.
Current taxation
Current tax is recognised in profit or loss, except for taxes related to revaluations of land and buildings which are recognised in other comprehensive income. Current tax represents the amount of tax payable (receivable) in respect of taxable profit (loss) for the current, or past, reporting periods. Current tax is measured at the amount expected to be paid (recovered) using the tax rates and laws which have been enacted, or substantively enacted, by the balance sheet date. Where payments to HM Revenue and Customs exceed liabilities owed, an asset is recognised to the extent of the amount of tax recoverable.
Tangible fixed assets and depreciation
All fixed assets are initially recorded at cost. Property, plant and equipment is used in the company's principal activity for the production and supply of goods or for administrative purposes and is stated in the balance sheet under the historic cost model. This model requires the assets to be stated at cost less amounts in respect of depreciation and less any accumulated impairment losses. Depreciation is calculated so as to write off the cost of an asset, less its estimated residual value (which is the expected amount that would currently be obtained from disposal of an asset, after deducting the estimated costs of disposal, if the asset were already of the age and in the condition expected at the end of its useful life), over the useful economic life of the respective asset as follows:

Reducing balance (%)
Fixtures and fittings25
Vehicles25
Office Equipment50
2.Average number of employees

20242023
Average number of employees during the year22
3.Tangible fixed assets

Land & buildings

Vehicles

Fixtures & fittings

Office Equipment

Total

£££££
Cost or valuation
At 01 October 2399,33189,3076,12329,575224,336
Additions74,118-3,7312,03879,887
Disposals(173,449)---(173,449)
At 30 September 24-89,3079,85431,613130,774
Depreciation and impairment
At 01 October 23-50,8984,49423,35678,748
Charge for year-9,6021,3404,12815,070
At 30 September 24-60,5005,83427,48493,818
Net book value
At 30 September 24-28,8074,0204,12936,956
At 30 September 2399,33138,4091,6296,219145,588
4.Debtors: amounts due within one year

2024

2023

££
Trade debtors / trade receivables87,41484,166
Other debtors-5,078
Prepayments and accrued income-4,298
Total87,41493,542
5.Creditors: amounts due within one year

2024

2023

££
Trade creditors / trade payables2,578482
Taxation and social security97,52269,831
Other creditors1,1671,020
Accrued liabilities and deferred income2,8512,851
Total104,11874,184
6.Creditors: amounts due after one year

2024

2023

££
Bank borrowings and overdrafts19,91229,925
Total19,91229,925